We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Nanopore Sequencing Rapidly Diagnoses Gut Condition in Preterm Infants

By LabMedica International staff writers
Posted on 03 Jan 2020
Print article
Image: Flongle is an adapter (flow cell dongle) for the MinION or GridION that enables direct, real-time DNA or RNA sequencing on smaller, single-use flow cells (Photo courtesy of Oxford Nanopore Technologies).
Image: Flongle is an adapter (flow cell dongle) for the MinION or GridION that enables direct, real-time DNA or RNA sequencing on smaller, single-use flow cells (Photo courtesy of Oxford Nanopore Technologies).
The culture-independent, sensitive, data-rich nature of metagenomic sequencing, combined with powerful bioinformatics tools, have allowed scientists to differentiate patient groups from healthy individuals based on their microbial profiles.

Metagenomics also allows the identification of functional traits, for example, antibiotic resistance genes, which are important in light of the antimicrobial resistance (AMR) threat. Optimization of metagenomic methodologies and bioinformatics tools could allow the identification of at-risk individuals, profiling of infectious agents and tailoring of treatments.

Scientists at the Earlham Institute (Norwich, UK) and their associates used the MinION platform (Oxford Nanopore Technologies, Oxford Science Park, UK) coupled to the Institute’s NanoOK RT software package to perform shotgun metagenomic sequencing and profile mock communities and fecal samples from healthy and ill preterm infants. The metagenomic nanopore sequencing was used to rapidly diagnose preterm infants with suspected necrotizing enterocolitis (NEC), a life-threatening gut condition, identifying pathogens and antimicrobial resistance genes in the gut microbiome within a few hours.

The Nanopore data reliably classified a 20-species mock community and captured the diversity of the immature gut microbiota over time and in response to interventions such as probiotic supplementation, antibiotic treatment or episodes of suspected sepsis. The team also performed rapid real-time runs to assess gut-associated microbial communities in critically ill and healthy infants, facilitated by NanoOK RT software package, which analyzed sequences as they were generated. The scientists compared their results with Illumina sequencing (Illumina, San Diego, CA, USA).

The team’s pipeline reliably identified pathogenic bacteria (that is, Klebsiella pneumoniae and Enterobacter cloacae) and their corresponding antimicrobial resistance gene profiles within as little as one hour of sequencing. Results were confirmed using pathogen isolation, whole-genome sequencing and antibiotic susceptibility testing, as well as mock communities and clinical samples with known antimicrobial resistance genes.

Lindsay J. Hall, PhD, a microbiologist and a senior author of the study, said, “The improvements via nanopore sequencing are the rapid nature and specificity of the test. This is very useful with very ill babies that need to be treated as quickly as possible, as well as providing key info for the clinician to treat with antibiotics likely to kill the bacteria. Current tests take much longer and might not catch all types of antibiotic resistance.”

The authors concluded that their results demonstrate that MinION (including cost-effective Flongle flow cells) with NanoOK RT can process metagenomic samples to a rich dataset in less than five hours, which creates a platform for future studies aimed at developing these tools and approaches in clinical settings with a focus on providing tailored patient antimicrobial treatment options. The study was published on December 16, 2019 in the journal Nature Microbiology.

Related Links:
Earlham Institute
Oxford Nanopore Technologies
Illumina


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.